Bellicum Pharmaceuticals, Inc. (BLCM)
Bellicum Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Houston, TX, US. The stock last traded at $0.07, down 6.68% on the session, giving a market capitalisation of $778,326. On trailing twelve-month figures it carries a trailing P/E of -0.09, a net margin of -1664.9%. Its beta of 1.38 implies it has historically moved more than the broad market.
Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations. BPX-601, an autologous therapy, targets solid tumors that exhibit the prostate stem cell antigen. Additionally, BPX-603, a dual-switch GoCAR-T treatment, is being investigated for solid tumors characterized by the human epidermal growth factor receptor 2 (HER2) antigens. The company also features Rivo-cel, an allogeneic T cell therapy designed to improve patient prognoses in cases of leukemias, lymphomas, and various inherited blood disorders. Bellicum maintains strategic partnerships and licensing arrangements with several entities, including Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Established in 2004, the company's corporate headquarters are located in Houston, Texas.
Bellicum Pharmaceuticals, Inc. is most often compared with the following Healthcare names: